Generated by All in One SEO v4.9.10, this is an llms.txt file, used by LLMs to index the site.

# Lincoln Pharmaceuticals

Healthcare for All

## Sitemaps

- [XML Sitemap](https://www.lincolnpharma.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [News](https://www.lincolnpharma.com/news/)
- [V.P - Lincoln Pharmaceuticals](https://www.lincolnpharma.com/marketing/v-p/) - PA-12 (AKA PARALIB In French West Africa ): The Hallmark of Convenience in Pain and Fever Management In a world where patient adherence, safety, and efficacy are paramount, PA-12, also known as PARALIB in French West Africa, emerges as a convenient and intelligent solution in the management of pain and fever. Engineered with PROGLET bilayer
- [UAT - Testing](https://www.lincolnpharma.com/innovation/uat-testing/) - This is sample of text for UAT.
- [V.P - Mayur Khakhar - Lincoln Pharma](https://www.lincolnpharma.com/innovation/v-p-mayur-khakhar-lincoln-pharma/) - Novel TAE benefit with Diclofenac gel of Lincoln Pharma with brand names like RELAXO/VIVIAN/DIKON/DIFLAME/DORGEL/DICLOGEL/DIKON PLUS/DICLIQUE/ALVIOL /DIPHADIC in various countries. Topical Relief, Scientific Innovation: Diclofenac Gel Reinvented for Enhanced Pain Management Dear Healthcare Professionals, We’re excited to share promising news in the treatment of pain with our Diclofenac Gel portfolio — now available in various countries
- [Lincoln Pharma's MD Shri Mahendrabhai Patel - Interview on ET Now](https://www.lincolnpharma.com/news/lincoln-pharmas-md-shri-mahendrabhai-patel-interview-on-et-now/) - Interview of Lincoln Pharma's MD Shri Mahendrabhai Patel on ET Now
- [Shri Mahendra G Patel, CMD - Lincoln Pharma - on 140 years of BSE](https://www.lincolnpharma.com/news/shri-mahendra-g-patel-cmd-lincoln-pharma-on-140-years-of-bse/) - Shri Mahendra G Patel, CMD - Lincoln Pharma - on 140 years of BSE
- [IPHEX 2017 Exhibition | Interview of MD Shri Mahendra G Patel with Hybiz TV | Hyderabad](https://www.lincolnpharma.com/news/iphex-2017-exhibition-interview-of-md-shri-mahendra-g-patel-with-hybiz-tv-hyderabad/) - Mahendra G. Patel, Lincoln Pharmaceuticals. IPHEX 2017 Pharma and Health Care Exhibition Hyderabad
- [Sanjay Raval with Pharma Entrepreneur Mahendrabhai G Patel | MD, Lincoln Pharma](https://www.lincolnpharma.com/news/sanjay-raval-with-pharma-entrepreneur-mahendrabhai-g-patel-md-lincoln-pharma/) - Had a great talk with Mr.Mahendrabhai G Patel, a true inspiration for young entrepreneurs.
- [Lincoln Pharma Reports Steady Q1 Earnings : Halftime Report](https://www.lincolnpharma.com/news/lincoln-pharma-reports-steady-q1-earnings-halftime-report/) - Lincoln Pharmaceuticals on Thursday reported a 20.44 per cent rise in its consolidated net profit to Rs 15.26 crore for the quarter ended June 30, 2020.
- [Leader Speaks - Interview of MD Shri Mahendra G Patel with IIFL Securities](https://www.lincolnpharma.com/news/leader-speaks-interview-of-md-shri-mahendra-g-patel-with-iifl-securities/) - "In an exclusive interaction with Shweta Papriwal, Editor, IIFL Securities, Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Ltd spoke about the company's international business and growth outlook going ahead.
- [Lincoln Pharma MD Shri Mahendra Patel Talks On Q4 Results In Conversation with Anil Singhvi](https://www.lincolnpharma.com/news/lincoln-pharma-md-mahendra-patel-talks-on-q4-results-in-conversation-with-anil-singhvi/) - "In an exclusive interaction with Anil Singhvi, Zee Business, Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Ltd spoke about the company's international business and growth outlook going ahead.
- [Lincoln Pharma MD Shri Mahendra Patel Talks on Q4 Results In Conversation with CNBC Bazaar](https://www.lincolnpharma.com/news/lincoln-pharma-md-shri-mahendra-patel-talks-on-q4-results-in-conversation-with-cnbc-bazaar/) - "In an exclusive interaction with CNBC Bazaar, Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Ltd spoke about the company's international business and growth outlook going ahead.
- [Lincoln Pharma MD Shri Mahendra Patel Talks on Budget 2023-2024 with CNBC Bazaar (Before Budget Speech by Finance Minister)](https://www.lincolnpharma.com/news/lincoln-pharma-md-shri-mahendra-patel-talks-on-budget-2023-2024-with-cnbc-bazaar/) - "In an exclusive interaction with CNBC Bazaar, Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Ltd spoke about the company's international business and growth outlook going ahead.
- [Lincoln Pharma MD Shri Mahendra Patel Talks on Budget 2023-2024 with CNBC Bazaar (After Budget Speech by Finance Minister)](https://www.lincolnpharma.com/news/lincoln-pharma-md-shri-mahendra-patel-talks-on-budget-2023-2024-with-cnbc-bazaar-after-budget-speech-by-finance-minister/) - "In an exclusive interaction with CNBC Bazaar, Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Ltd spoke about the company's international business and growth outlook going ahead.
- [Lincoln Pharma Director Mr. Munjal Patel's Exclusive Interview with CNBC Bajar](https://www.lincolnpharma.com/news/lincoln-pharma-director-mr-munjal-patels-exclusive-interview-with-cnbc-bajar/) - "In an exclusive interaction with CNBC Bazaar, Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Ltd spoke about the company's international business and growth outlook going ahead.
- [Lincoln Pharma Director Mr. Munjal Patel's Exclusive Interview with Zee Business - Corporate Radar](https://www.lincolnpharma.com/news/lincoln-pharma-director-mr-munjal-patels-exclusive-interview-with-zee-business-corporate-radar/) - "In an exclusive interaction with CNBC Bazaar, Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Ltd spoke about the company's international business and growth outlook going ahead.
- [Lincoln Pharma Managing Director Mr. Mahendra Patel & Director Mr. Munjal Patel's Exclusive Interview with CNBC Bajar](https://www.lincolnpharma.com/news/lincoln-pharma-managing-director-mr-mahendra-patel-director-mr-munjal-patels-exclusive-interview-with-cnbc-bajar/) - "In an exclusive interaction with CNBC Bazaar, Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Ltd spoke about the company's international business and growth outlook going ahead.
- [Lincoln Pharmaceuticals is on this Elite Club for having shown consistent profit growth](https://www.lincolnpharma.com/news/lincoln-pharmaceuticals-is-on-this-elite-club-for-having-shown-consistent-profit-growth/) - Stock picking is not easy. It is about analysis. It is about avoiding the landmines. It is about position sizing. It is about risk management. It is about having no ego to pull out when your thesis doesn't play out. Here is a data point that Devina Mehra, founder and CMD of First Global, shares. Followed by
- [Lincoln Pharmaceuticals Ltd posts consolidated PAT of Rs. 19.01 crores in Q1FY24](https://www.lincolnpharma.com/news/lincoln-pharmaceuticals-ltd-posts-consolidated-pat-of-rs-19-01-crores-in-q1fy24/) - Read full article here. Lincoln Pharmaceuticals Limited has reported Consolidated financial results for the period ended June 30, 2023. Financial Results (Q1 FY2024) - QoQ Comparison The company has reported total income of Rs. 143.3103 crores during the period ended June 30, 2023 as compared to Rs. 116.3588 crores during the period ended March 31,

## Pages

- [Home](https://www.lincolnpharma.com/) - Welcome to Lincoln PharmaceuticalsProviding Affordable & Innovative medicines for healthier lives. To spark a universal attempt to uncover cures of diseases by focused and targeted R&D, through forging Strategic alliances both domestically and internationally. Robust Quality Control Process cGMP Training Programs Ensures SOP Compliance Niche QA Department Presence over 60+ Countries Maintaining Industry Standards 100+
- [Integrated Corporate Governance](https://www.lincolnpharma.com/investor/other-disclosures/corporate-governance/) - 2026-2027 Q1 2025-2026 Q1 Q2 Q3 Q4 2024-2025 Q1 Q2 Q3 Q4 2023-2024 Q1 Q2 Q3 Q4 2022-2023 Q1 Q2 Q3 Q4 2021-2022 Q1 Q2 Q3 Q4 2020-2021 Q1 Q2 Q3 Q4 2019-2020 Q1 Q2 Q3 Q4 2018-2019 Q1 Q2 Q3 Q4 2017-2018 Q1 Q2 Q3 Q4
- [Shareholding Patterns](https://www.lincolnpharma.com/investor/disclosures-under-regulation-46-of-the-lodr/shareholding-patterns/) - 2026-2027 Q1 2025-2026 Q1 Q2 Q3 Q4 2024-2025 Q1 Q2 Q3 Q4 2023-2024 Q1 Q2 Q3 Q4 2022-2023 Q1 Q2 Q3 Q4 2021-2022 Q1 Q2 Q3 Q4 2020-2021 Q1 Q2 Q3 Q4 2019-2020 Q1 Q2 Q3 Q4 2018-2019 Q1 Q2 Q3 Q4
- [Investors](https://www.lincolnpharma.com/investor/) - Special Window open for Re-lodgement of Transfer requests of Physical Shares (Only requests Lodged before 31.03.2021 which is rejected/returned and not for fresh transfer) Window open till February 04, 2027 SPECIAL WINDOW FOR RE-LODGEMENT OF TRANSFER REQUESTS OF PHYSICAL SHARES – February 05, 2026 to February 04, 2027 Disclosures under Regulation 46 of the LODR
- [Newspaper Advertisement](https://www.lincolnpharma.com/investor/disclosures-under-regulation-46-of-the-lodr/newspaper-advertisement/) - 2025-2026 AGM Newspaper Ad-Before Dispatch of Notice AGM Newspaper Ad-After Dispatch of Notice Special Window for Re-lodgment of Transfer Requests Physical Shares Publication of Financial Results 30-06-2025 Publication of Financial Results 30-09-2025 Publication of Financial Results 31-12-2025 Publication of Financial Results 31-03-2026 2024-2025 Postal Ballot Notice Dispatch Adv. AGM Newspaper Ad-Before Dispatch of Notice AGM
- [Investor Presentations](https://www.lincolnpharma.com/investor/disclosures-under-regulation-46-of-the-lodr/investor-presentations/) - 2025-2026 Q1 Q2 Q3 Q4 2024-2025 Q1 Q2 Q3 Q4 2023-2024 Q1 Q2 Q3 Q4 2022-2023 Q1 Q2 Q3 Q4 2021-2022 Q1 Q2 Q3 Q4 2020-2021 Q1 Q2 Q3 Q4 2019-2020 Q1 Q2 Q3 Q4 2018-2019 Q1 Q2 Q3 Q4 2017-2018 Q1 Q2 Q3 Q4
- [AI DEMO](https://www.lincolnpharma.com/ai-demo/) - HelicoPEDIA – Issue 1 Clinical Series on Helicobacter pylori · Issue 1 " Clinical Series on Helicobacter pylori "Updated Guidelines for H. pylori Eradication: Optimizing Treatment in the Era of Rising Antibiotic Resistance" 50% Global Prevalence #1 Group I Carcinogen 15% Resistance Threshold 5 Key Guideline Updates Explore 💡 Did You Know? 50% of the
- [FIFA 2026](https://www.lincolnpharma.com/fifa-2026/) - FR EN ★★★ Concours de pronostics FIFA Champion Contenu terminé Détails du participant Nom : Pays : Spécialité : Numéro de contact / ID e-mail : 1. QUART DE FINALISTES CHOISISSEZ 8 ÉQUIPES 2. DEMI-FINALISTES CHOISISSEZ 4 ÉQUIPES 3. FINALISTES CHOISISSEZ 2 ÉQUIPES VAINQUEUR Soumettre les prédictions AVEC LA COMPLICITÉ DE
- [Related Party Transactions](https://www.lincolnpharma.com/investor/other-disclosures/related-party-transactions/) - 2025-2026 Related Party Transactions 30-09-2025 Related Party Transactions 31-03-2026 2024-2025 Related Party Transactions 30-09-2024 Related Party Transactions 31-03-2025 2023-2024 Related Party Transactions 30-09-2023 Related Party Transactions 31-03-2024 2022-2023 Related Party Transactions 30-09-2022 Related Party Transactions 31-03-2023 2021-2022 Related Party Transactions-30-09-2021 Related Party Transactions-31-03-2022
- [Financial Results](https://www.lincolnpharma.com/investor/disclosures-under-regulation-46-of-the-lodr/financial-results/) - 2025-2026 Q1 Q2 Q3 Q4 2024-2025 Q1 Q2 Q3 Q4 2023-2024 Q1 Q2 Q3 Q4 2022-2023 Q1 Q2 Q3 Q4 2021-2022 Q1 Q2 Q3 Q4 2020-2021 Q1 Q2 Q3 Q4 2019-2020 Q1 Q2 Q3 Q4 2018-2019 Q1 Q2 Q3 Q4 2017-2018 Q1 Q2 Q3 Q4
- [Outcome of Board Meetings](https://www.lincolnpharma.com/investor/disclosures-under-regulation-46-of-the-lodr/outcome-of-board-meetings/) - 2025-2026 Q1 Q2 Q3 Q4 2024-2025 Q1 Q2 Q3 Q4 2023-2024 Q1 Q2 Q3 Q4 Appointment of ID, Reconstitution of Committee & Postal Ballot 2022-2023 Q1 Q2 Q3 Q4 Reconstitution of Committees 2021-2022 Q1 Q2 Q3 Q4 Allotment of Shares 2020-2021 Q1 Q2 Q3 Q4 2019-2020 Q1 Q2 Q3 Q4 Approved Interim Dividend of Rs.
- [Corporate Notices](https://www.lincolnpharma.com/investor/disclosures-under-regulation-46-of-the-lodr/corporate-notices/) - 2026-2027 Meeting on 28-05-2026 2025-2026 Meeting on 22-05-2025 Meeting on 13-11-2025 Meeting on 07-08-2025 Meeting on 12-02-2026 2024-2025 Meeting on 13-02-2025 Meeting on 14-11-2024 Meeting on 08-08-2024 Meeting on 16-05-2024 2023-2024 Meeting on 25-05-2023 Meeting on 02-11-2023 Meeting on 10-08-2023 Meeting on 08-02-2024 2022-2023 Meeting on 09-08-2022 Meeting on 10-11-2022 Meeting on 09-02-2023 Meeting on
- [Disclosures under sub-regulation (8) of Regulation 30](https://www.lincolnpharma.com/investor/disclosures-under-regulation-46-of-the-lodr/disclosures-under-sub-regulation-8-of-regulation-30/) - 2025-2026 AGM/EGMBoard MeetingCompany UpdateCorp. ActionInsider Trading / SASTNew ListingResultIntegrated FillingAGM/EGM Minutes Of 31St Annual General Meeting Of The Company Shareholder Meeting / Postal Ballot-Scrutinizer”s Report Submission Of E-Voting Results Of 31St AGM Along With The Scrutinizer Report As Per Regulation 44 Of SEBI (LODR) Regulation, 2015 Shareholder Meeting / Postal Ballot-Outcome of AGM Notice Of
- [Secretarial Compliance Report](https://www.lincolnpharma.com/investor/disclosures-under-regulation-46-of-the-lodr/secretarial-compliance-report/) - 2025-2026 Secretarial Compliance Report 2024-2025 Secretarial Compliance Report 2023-2024 Secretarial Compliance Report 2022-2023 Secretarial Compliance Report 2021-2022 Secretarial Compliance Report 2020-2021 Secretarial Compliance Report 2019-2020 Secretarial Compliance Report
- [Contact](https://www.lincolnpharma.com/contact/) - Lincoln Pharmaceuticals Ltd. “Lincoln House” B/h Satyam Complex, Science City Road, Sola, Ahmedabad-380060, Gujarat, India. Phone number: +91-79-41078000 E-mail: info@lincolnpharma.com Please enable JavaScript in your browser to complete this form.Please enable JavaScript in your browser to complete this form.Name *Email *SubjectMessageSubmit
- [Familiarization Policy](https://www.lincolnpharma.com/investor/other-policies/familiarization-policy/) - Policy Details 2025-2026 Familiarization Programme 2024-2025 Familiarization Programme 2023-2024 Familiarization Programme 2022-2023 Familiarization Programme 2021-20222020-2021 Familiarization Programme 2019-2020 Familiarization Programme 2018-2019 Familiarization Programme 2017-2018 Familiarization Programme
- [API Operations](https://www.lincolnpharma.com/api/api-operations/) - About API Division “Our Founder member and VINSON of Lincoln pharmaceuticals ltd Shri Rajanibhai G Patel has given direction to the company over last four decades. A vision that has breathed life in our Mission to heal and protect lives of billions of hearts across the world. Lincoln has grown and evolved over various type
- [API Products](https://www.lincolnpharma.com/api/api-products/)
- [API Contact](https://www.lincolnpharma.com/api/api-contact/) - Lincoln Pharmaceuticals Ltd. – HO “Lincoln House” B/h Satyam Complex, Science City Road, Sola, Ahmedabad-380060, Gujarat, India. Lincoln Pharmaceuticals Ltd. – Plant Block No.-176 (Old Block No.95/5 A+B), Trimul Estate, Khatraj,, Ta : Kalol, Dist : Gandhinagar, CIN : L24230GJ1995PLC024288, KHATRAJ -382721, GUJARAT, INDIA Phone number:+91-79-41078029 E-mail:apisales@lincolnpharma.com
- [API](https://www.lincolnpharma.com/api/)
- [Investors Call](https://www.lincolnpharma.com/investor/disclosures-under-regulation-46-of-the-lodr/investors-call/) - 2025-2026 Investor Conference Call Intimation Conference Call Audio Investor Call Transcript-18th February, 2026 2023-2024 Q4 Investor Conference Call Intimation Investor Call Transcript-16th May, 2024 Conference Call Audio
- [Unpaid Dividend Data](https://www.lincolnpharma.com/investor/other-disclosures/unpaid-dividend-data/) - 2024-2025 Statement of Unpaid Dividend 2023-2024 Statement of Unpaid Dividend 2022-2023 Statement of Unpaid Dividend 2021-2022 Statement of Unpaid Dividend 2020-2021 Statement of Unpaid Dividend 2019-2020 Statement of Unpaid Dividend 2018-2019 Statement of Unpaid Dividend 2017-2018 Statement of Unpaid Dividend
- [Lincoln Voice](https://www.lincolnpharma.com/lincoln-voice/) - Vol 1 Vol 2 Vol 3
- [IEPF Suspense Account](https://www.lincolnpharma.com/investor/other-disclosures/iepf-suspense-account/) - 2024-2025 IEPF Suspense Account 2023-2024 IEPF Suspense Account 2022-2023 IEPF Suspense Account 2021-2022 IEPF Suspense Account 2020-2021 IEPF Suspense Account 2019-2020 IEPF Suspense Account 2018-2019 IEPF Suspense Account 2017-2018 IEPF Suspense Account
- [Credit Rating](https://www.lincolnpharma.com/investor/disclosures-under-regulation-46-of-the-lodr/credit-rating/) - 2025-2026 Re-affirmation of Credit Rating by CRISIL 2020-2021 Report 2019-2020 Report
- [AGM-EGM Results](https://www.lincolnpharma.com/investor/disclosures-under-regulation-46-of-the-lodr/agm-egm-results/) - 2024-2025 Script of the AGM Outcome of AGM Scrutinizer and E-voting Report 2023-2024 Script of the AGM Outcome of AGM Scrutinizer and E-voting Report 2022-2023 Scrutinizer and E-voting Report Outcome of AGM Script of the AGM 2021-2022 Scrutinizer and E-voting Report Out Come of the AGM Script of the AGM 2020-2021 Scrutinizer and E-voting Report
- [Financials of Subsidiary](https://www.lincolnpharma.com/investor/disclosures-under-regulation-46-of-the-lodr/financials-of-subsidiary/) - 2024-2025 Zullinc Healthcare LLP Annual Report 2023-2024 Zullinc Healthcare LLP Annual Report 2022-2023 Zullinc Healthcare LLP Annual Report 2021-2022 Zullinc Healthcare LLP Annual Report 2020-2021 Zullinc Healthcare LLP Annual Report 2019-2020 Lincoln Parenteral Limited Annual Report Zullinc Healthcare LLP Annual Report 2018-2019 Lincoln Parenteral Limited Annual Report Zullinc Healthcare LLP Annual Report 2017-2018 Lincoln Parenteral
- [Annual Report](https://www.lincolnpharma.com/investor/disclosures-under-regulation-46-of-the-lodr/annual-report/) - 2024-2025 Dispatch of Physical communication to Shareholders Notice of AGM Annual Report 2023-2024 Notice of AGM Annual Report 2022-2023 Notice of AGM Annual Report 2021-2022 Notice of AGM Annual Report 2020-2021 Notice of AGM Annual Report 2019-2020 Notice of AGM Annual Report 2018-2019 Notice of AGM Annual Report 2017-2018 Notice of AGM Annual Report
- [MGT-7 Annual Return](https://www.lincolnpharma.com/investor/disclosures-under-regulation-46-of-the-lodr/mgt-7annual-return/) - 2024-2025 Annual Return 2023-2024 Annual Return 2022-2023 Annual Return 2021-2022 Annual Return 2020-2021 Annual Return
- [Disclosures under Regulation 46 of the LODR](https://www.lincolnpharma.com/investor/disclosures-under-regulation-46-of-the-lodr/) - Detail of Business MOA-AOA Brief Profile of Directors Terms and conditions of appointment of Independent Directors Composition of various committees of Board of Directors Code of conduct for Board of Directors & Senior Management Personnel Details of establishment of Whistle Blower Policy Policy on Related Party Transactions Familiarization program for Independent Directors Dividend Distribution Policy
- [Nourishing Education & Empowering Women](https://www.lincolnpharma.com/activities/nourishing-education-empowering-women/) - Saraswati Kanya Kelvani Mandal, Mehsana INTRO Shree Saraswati Kanya Kelvani Mandal, founded in 1964 in Nanikadi near Kadi, Mehsana, is a prestigious women’s educational trust established by the Patidar community. What began as a modest hostel and school has evolved into a full-fledged institution offering nursery to post-graduate education, including science, commerce, nursing, and teacher
- [Activities](https://www.lincolnpharma.com/activities/) - CSR (Corporate Social Responsibility) at a Glance At Lincoln Pharmaceuticals, our conviction is clear: Healthcare for All isn’t just our tagline—it’s our mission. Our CSR efforts span nearly two decades, empowering vulnerable communities across education, health, environment, and inclusive growth. Here’s a refreshed, engaging draft to showcase on your website: CSR in Various Fields At
- [Healthcare Access for Underserved Communities](https://www.lincolnpharma.com/activities/healthcare-access-for-underserved-communities/) - Bhagyoday Hospital, Kadi & Medical College INTRO A charitable multi-specialty hospital serving Kadi and 300+ villages with affordable healthcare across 12+ departments. WHAT WE DID – Contributed to surgeries and patient care – Donated funds for the establishment of Bhagyoday Medical College IMPACT Improved access to quality healthcare and medical education in rural Gujarat. Sri
- [Cultural, Educational & National Pride](https://www.lincolnpharma.com/activities/cultural-educational-national-pride/) - Saptak School of Music INTRO A premier institution based in Ahmedabad, Saptak is renowned for preserving and promoting Indian classical music through education and its annual music festival, which attracts top-tier artists and audiences nationwide. WHAT WE DID Sponsored music education programs Supported the prestigious Saptak Annual Music Festival, celebrating India’s classical arts and cultural
- [Greening the Planet](https://www.lincolnpharma.com/activities/greening-the-planet/) - Green Leaf Trust, Setu Trust & Vicharta Samuday Samarthan Manch INTRO Green Leaf Trust, Setu Trust, and Vicharta Samuday Samarthan Manch (VSSM) are grassroots organizations dedicated to sustainable development and environmental conservation in Gujarat. These NGOs focus on improving ecological balance through afforestation, watershed management, and supporting water-scarce communities with innovative conservation practices. Operating across
- [Empowering the Differently Abled](https://www.lincolnpharma.com/activities/empowering-the-differently-abled/) - Blind People’s Association (BPA), Ahmedabad INTRO The Blind People’s Association, founded in 1954 in Ahmedabad by Padma Shri recipient Jagdish Kashibhai Patel, is a pioneering NGO dedicated to comprehensive rehabilitation of individuals with visual, hearing, mental, orthopedic, and multiple disabilities. BPA operates multiple education and vocational training centers, physiotherapy and technical schools, a Braille production
- [Community Upliftment & Rural Livelihood](https://www.lincolnpharma.com/activities/community-upliftment-rural-livelihood/) - Vicharta Samuday Samarthan Manch (VSSM) & Vimukt Foundation INTRO VSSM, formally registered in 2010 and led by social activist Mittal Patel, is a dedicated non-profit committed to empowering nomadic and de-notified communities across Gujarat. With a presence in over 5,000 settlements and outreach to more than 200,000 families, VSSM champions education, housing, livelihood, water conservation,
- [Domestic Products](https://www.lincolnpharma.com/domestic/domestic-products/)
- [Other Disclosures](https://www.lincolnpharma.com/investor/other-disclosures/) - Board of Directors Disclosure on Material Impact of CoVID-19 Availability of Dispute Resolution Mechanism at Stock Exchanges Integrated Corporate Governance Unpaid Dividend Data as per Sec. 124(2) of the Companies Act, 2013 IEPF Suspense Account Scheme of Amalgamation Code of Conduct TDS Formats Related Party Transactions Media Release Press Release Dematerialization Of Physical Securities Details Of
- [About Us](https://www.lincolnpharma.com/about-us/) - Lincoln PharmaceuticalsWHO WE AREYou are here:HomePageAbout UsWho We Are Lincoln Pharmaceutical Company was established in 1979 by Mr. Rajani G. Patel and Mr. Hasmukhbhai I. Patel as a founder member with other fellow partners. Gradually, the Company was expanding its reach in the Domestic market. In the year 1990, Mr. Mahendra G. Patel also joined
- [Certifications](https://www.lincolnpharma.com/manufacturing/certifications/) - EUGMP, cGMP, WHO-GMP and ISO 9001:2015 Certified Lincoln’s Khatraj manufacturing facilities fulfills the cGMP guidelines and abides with WHO, cGMP norms and are certified by WHO GMP and ISO 9001:2015. A wide range of regulatory agencies routinely conduct stringent audits of our manufacturing facilities for compliance with Current Good Manufacturing Practices (cGMP). Commitment to quality
- [KYC Compliance](https://www.lincolnpharma.com/investor/other-disclosures/kyc-compliance/) - SEBI – Issuance of Securities in dematerialized form in case of Investor Service Requests Common and Simplified Norms for processing investor’s service request by RTAs Letter to Shareholders SEBI Circular-Done away with freezing Folio Form ISR-4 Formats for KYC
- [Business Opportunity](https://www.lincolnpharma.com/manufacturing/business-opportunity/) - Collaborate for Contract Manufacturing and R&DYour Needs – Our InfrastructureLincoln Pharma offers contract manufacturing facilities for verticals like pharmaceuticals, food supplements, nutraceuticals, and vitamins. This contract manufacturing facilities were evolved prior to fixed up the agreement as per the best practice of industries and ensures that it is in compliance with “GMP Requirement”. Additionally dedicated
- [New Launches](https://www.lincolnpharma.com/portfolio/new-launches/) - Progesterone Spray Unique delivery system for accurate 25mg delivery of micronized progesterone/Spray Better patient compliance than vaginal tablets, capsules and painful intramuscular injections Formulation dispensed in mist form which provides local as well as systemic effect of Progesterone via vaginal route covering large area of vaginal cavity Paracetamol 1000 mg programmed release tablet Unique bi
- [Collaboration](https://www.lincolnpharma.com/r-d/collaboration/) - Collaboration in R&D / Business Opportunity We are always open to partnerships and analyze new business avenues and opportunities. If you think you have a strategy or research wing and want to collaborate with us for product formulation, kindly get in touch with us and we will try our best to leverage both of our
- [Contact Info](https://www.lincolnpharma.com/international/contact-info/) - To impanel as a distributor or to get into a professional association internationally, our contact details are as below: Mr. Munjal M. Patel Whole Time Director info@lincolnpharma.com Integrazione Neteller nelle Piattaforme secondo Scommezoid Studio L’integrazione di Neteller nelle piattaforme digitali rappresenta uno degli sviluppi più significativi nel panorama dei pagamenti online degli ultimi anni. Questo
- [Capabilities](https://www.lincolnpharma.com/manufacturing/capabilities/) - Company develops and manufactures affordable and innovative medicines for healthier lives for more than 60 countries worldwide Manufacturing proficiency has been Lincoln Pharma’s forte ever since its inception. We have ensured world-class quality in design, equipment and operations in our manufacturing facilities. Our units ensure that we are able to provide best-in-class products to patients
- [Submit Blog](https://www.lincolnpharma.com/submit-blog/)
- [Blog](https://www.lincolnpharma.com/blog/) - V.P – Mayur Khakhar – Lincoln Pharma Novel TAE benefit with Diclofenac gel of Lincoln Pharma with brand names like RELAXO/VIVIAN/DIKON/DIFLAME/DORGEL/DICLOGEL/DIKON PLUS/DICLIQUE/ALVIOL /DIPHADIC in various countries. Topical Relief, Scientific Innovation: Diclofenac Gel Reinvented for Enhanced Pain Management Dear Healthcare Professionals, We’re excited to share promising news in the treatment of pain with our Diclofenac Gel
- [Testing Blog](https://www.lincolnpharma.com/testing-blog/) - V.P – Mayur Khakhar – Lincoln PharmaNovel TAE benefit with Diclofenac gel of Lincoln Pharma with brand names like RELAXO/VIVIAN/DIKON/DIFLAME/DORGEL/DICLOGEL/DIKON PLUS/DICLIQUE/ALVIOL /DIPHADIC in various countries. Topical Relief, Scientific Innovation: Diclofenac Gel Reinvented for Enhanced Pain Management Dear Healthcare Professionals, We’re excited to share promising news in the treatment of pain with our Diclofenac Gel portfolio
- [Integrated Filing(Financials)](https://www.lincolnpharma.com/investor/disclosures-under-regulation-46-of-the-lodr/integrated-filingfinancials/) - 2024-2025 31-12-2024
- [Diwali 2024](https://www.lincolnpharma.com/diwali-2024/) - Diwali Traditional Day - 2024
- [Navratri 2024](https://www.lincolnpharma.com/navratri-2024/) - Green DayGrey DayWhite DayRed DayRoyal Blue DayPink Day
- [BRSR](https://www.lincolnpharma.com/investor/disclosures-under-regulation-46-of-the-lodr/brsr/) - 2023-2024 2022-2023
- [Other Policies](https://www.lincolnpharma.com/investor/other-policies/) - Corporate Social Responsibility Policy Performance Evaluation of the Directors Performance Evaluation of the Independent Directors Archival Policy Risk Management Policy Policy on Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information Policy on prevention of sexual harassment (POSH) Policy on Preservation of Documents
- [Lincoln Talent Hunt 2023](https://www.lincolnpharma.com/lincoln-talent-hunt-2023/) - [integrate_google_drive id="2"]
- [Walk In Application](https://www.lincolnpharma.com/walk-in-application/)
- [Careers](https://www.lincolnpharma.com/careers/) - We just achieved milestone of Rs. 500 Crore revenue and Rs. 100 Crore Profit before tax in FY23. Lincoln Pharmaceuticals Limited is one of the leading healthcare companies in Gujarat, India. Established in the year 1979, the company develops and manufactures affordable and innovative medicines for healthier lives. The company has developed 600 plus formulations
- [Application Privacy Policy](https://www.lincolnpharma.com/application-privacy-policy/) - Privacy Policy This privacy policy sets out how Lincoln Online uses and protects any information that you give us while using this Mobile application. Lincoln Online is highly committed to ensuring the protection of your privacy. If we ask you to provide certain information by which you can be identified when using this Mobile Application,
- [LPL GARBA 2023](https://www.lincolnpharma.com/lpl-garba-2023/) - [integrate_google_drive id="1"]
- [Jobs](https://www.lincolnpharma.com/job-openings/)
- [TDS Formats](https://www.lincolnpharma.com/investor/other-disclosures/tds-formats/) - Form 10F Form 15G Form 15H Self Declaration
- [Outcome of BM](https://www.lincolnpharma.com/investor/outcome-of-bm/) - Updates from Lincoln Pharmaceuticals Limited2022-2023 Q1 Q2 Q3 Q4 Reconstitution of Committees Updates from BSE IndiaInsider Trading / SASTCompany UpdateResultBoard MeetingAGM/EGMCorp. ActionInsider Trading / SAST Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations, 2011 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 Disclosures under Reg. 29(2) of
- [Media Release](https://www.lincolnpharma.com/investor/other-disclosures/media-release/) - Launch of Vitamin C+ Zinc Tablets Receiving European Union (EU) GMP Approval
- [Press Release](https://www.lincolnpharma.com/investor/other-disclosures/press-release/) - Awarded Patent Antimalarial Drug Developed NDDS formulation Ondansetron Oral Spray (Domi Up) Launches Vaginal Spray Receives a Patent for Diclofenac Rectal Spray
- [Investor Information](https://www.lincolnpharma.com/investor/other-disclosures/investor-information/) - Media Release On Vitamin C Launch Intimation Under Reg 30 Of Sebi (Lodr) Board Of Directors Code Of Conduct Investor Information Terms And Condition Of Appointment Of Independent Director Notice Regarding Change Of Rta. Press Release Press Release — Launches Vaginal Spray Press Release On Ndds Formulation Ondansetron Oral Spray (Domi Up) A.G.M.-2016 Scrutinizer Report
- [Scheme of Amalgamation](https://www.lincolnpharma.com/investor/other-disclosures/scheme-of-amalgamation/) - Prior Intimation to stock Exchange for Approve Draft Scheme of Ammalgamation Outcome of Board Meeting of Scheme of Amalgamation Audited Financials of Transferor & Transferee Cos. Independent Auditor’s Certificate Compliance Report Draft Scheme of Amalgamation Fairness Opinion by Merchant Banker Shareholding Pattern of Transferor & Transferee Cos. Report from the Audit Committee Valuation Report from
- [Code of Conduct](https://www.lincolnpharma.com/investor/other-disclosures/code-of-conduct/) - 2022-2023 Code of Conduct Code of Conduct for Insiders Trading Code of Practices and Procedures for fair Disclosure-of Unpublished Price Sensitive Information
- [For Investors](https://www.lincolnpharma.com/lplinvestors/) - For Investors Media Release On Vitamin C Launch Intimation Under Reg 30 Of Sebi (Lodr) Board Of Directors Code Of Conduct Investor Information Terms And Condition Of Appointment Of Independent Director Notice Regarding Change Of Rta. Press Release Press Release — Launches Vaginal Spray Press Release On Ndds Formulation Ondansetron Oral Spray (Domi Up) A.G.M.-2016
- [Corporate Social Responsibility Policy](https://www.lincolnpharma.com/investor/other-policies/corporate-social-responsibility-policy/) - 2022-2023 Q1 Q2 Q3 Q4 Q5 2021-2022 Q1 Q2 Q3 Q4 Q5 2020-2021 Q1 Q2 Q3 Q4 Q5 2019-2020 Q1 Q2 Q3 Q4 Q5 2018-2019 Q1 Q2 Q3 Q4 Q5 2017-2018 Q1 Q2 Q3 Q4 Q5 2016-2017 Q1 Q2 Q3 Q4 Q5 2015-2016 Q1 Q2 Q3 Q4 Q5
- [Performance Evaluation of the Independent Directors](https://www.lincolnpharma.com/investor/other-policies/performance-evaluation-of-the-independent-directors/) - 2022-2023 Q1 Q2 Q3 Q4 Q5 2021-2022 Q1 Q2 Q3 Q4 Q5 2020-2021 Q1 Q2 Q3 Q4 Q5 2019-2020 Q1 Q2 Q3 Q4 Q5 2018-2019 Q1 Q2 Q3 Q4 Q5 2017-2018 Q1 Q2 Q3 Q4 Q5 2016-2017 Q1 Q2 Q3 Q4 Q5 2015-2016 Q1 Q2 Q3 Q4 Q5
- [Performance Evaluation of the Directors](https://www.lincolnpharma.com/investor/other-policies/performance-evaluation-of-the-directors/) - 2022-2023 Q1 Q2 Q3 Q4 Q5 2021-2022 Q1 Q2 Q3 Q4 Q5 2020-2021 Q1 Q2 Q3 Q4 Q5 2019-2020 Q1 Q2 Q3 Q4 Q5 2018-2019 Q1 Q2 Q3 Q4 Q5 2017-2018 Q1 Q2 Q3 Q4 Q5 2016-2017 Q1 Q2 Q3 Q4 Q5 2015-2016 Q1 Q2 Q3 Q4 Q5
- [Nomination and Remuneration Policy](https://www.lincolnpharma.com/investor/other-policies/nomination-and-remuneration-policy/) - 2022-2023 Q1 Q2 Q3 Q4 Q5 2021-2022 Q1 Q2 Q3 Q4 Q5 2020-2021 Q1 Q2 Q3 Q4 Q5 2019-2020 Q1 Q2 Q3 Q4 Q5 2018-2019 Q1 Q2 Q3 Q4 Q5 2017-2018 Q1 Q2 Q3 Q4 Q5 2016-2017 Q1 Q2 Q3 Q4 Q5 2015-2016 Q1 Q2 Q3 Q4 Q5
- [Investors Back Up](https://www.lincolnpharma.com/investors-back-up/) - For Investors Media Release On Vitamin C Launch Intimation Under Reg 30 Of Sebi (Lodr) Board Of Directors Code Of Conduct Investor Information Terms And Condition Of Appointment Of Independent Director Notice Regarding Change Of Rta. Press Release Press Release — Launches Vaginal Spray Press Release On Ndds Formulation Ondansetron Oral Spray (Domi Up) A.G.M.-2016
- [Change in officials of determining the Materiality of Events](https://www.lincolnpharma.com/investor/other-disclosures/change-in-officials-of-determining-the-materiality-of-events/) - 2022-2023 Q1 Q2 Q3 Q4 Q5 2021-2022 Q1 Q2 Q3 Q4 Q5 2020-2021 Q1 Q2 Q3 Q4 Q5 2019-2020 Q1 Q2 Q3 Q4 Q5 2018-2019 Q1 Q2 Q3 Q4 Q5 2017-2018 Q1 Q2 Q3 Q4 Q5 2016-2017 Q1 Q2 Q3 Q4 Q5 2015-2016 Q1 Q2 Q3 Q4 Q5
- [Board of Directors](https://www.lincolnpharma.com/investor/other-disclosures/board-of-directors/) - 2022-2023 Q1 Q2 Q3 Q4 Q5 2021-2022 Q1 Q2 Q3 Q4 Q5 2020-2021 Q1 Q2 Q3 Q4 Q5 2019-2020 Q1 Q2 Q3 Q4 Q5 2018-2019 Q1 Q2 Q3 Q4 Q5 2017-2018 Q1 Q2 Q3 Q4 Q5 2016-2017 Q1 Q2 Q3 Q4 Q5 2015-2016 Q1 Q2 Q3 Q4 Q5
- [Dividend Distribution Policy](https://www.lincolnpharma.com/investor/disclosures-under-regulation-46-of-the-lodr/dividend-distribution-policy/) - 2022-2023 Q1 Q2 Q3 Q4 Q5 2021-2022 Q1 Q2 Q3 Q4 Q5 2020-2021 Q1 Q2 Q3 Q4 Q5 2019-2020 Q1 Q2 Q3 Q4 Q5 2018-2019 Q1 Q2 Q3 Q4 Q5 2017-2018 Q1 Q2 Q3 Q4 Q5 2016-2017 Q1 Q2 Q3 Q4 Q5 2015-2016 Q1 Q2 Q3 Q4 Q5
- [Details-of-KMP-for-Determining-Materiality-of-Events](https://www.lincolnpharma.com/investor/disclosures-under-regulation-46-of-the-lodr/details-of-kmp-for-determining-materiality-of-events/) - 2022-2023 Q1 Q2 Q3 Q4 Q5 2021-2022 Q1 Q2 Q3 Q4 Q5 2020-2021 Q1 Q2 Q3 Q4 Q5 2019-2020 Q1 Q2 Q3 Q4 Q5 2018-2019 Q1 Q2 Q3 Q4 Q5 2017-2018 Q1 Q2 Q3 Q4 Q5 2016-2017 Q1 Q2 Q3 Q4 Q5 2015-2016 Q1 Q2 Q3 Q4 Q5
- [Policy for determination of Materiality of Events](https://www.lincolnpharma.com/investor/disclosures-under-regulation-46-of-the-lodr/policy-for-determination-of-materiality-of-events/) - 2022-2023 Q1 Q2 Q3 Q4 Q5 2021-2022 Q1 Q2 Q3 Q4 Q5 2020-2021 Q1 Q2 Q3 Q4 Q5 2019-2020 Q1 Q2 Q3 Q4 Q5 2018-2019 Q1 Q2 Q3 Q4 Q5 2017-2018 Q1 Q2 Q3 Q4 Q5 2016-2017 Q1 Q2 Q3 Q4 Q5 2015-2016 Q1 Q2 Q3 Q4 Q5
- [Shareholder Contacts](https://www.lincolnpharma.com/investor/disclosures-under-regulation-46-of-the-lodr/shareholder-contacts/) - 2022-2023 Q1 Q2 Q3 Q4 Q5 2021-2022 Q1 Q2 Q3 Q4 Q5 2020-2021 Q1 Q2 Q3 Q4 Q5 2019-2020 Q1 Q2 Q3 Q4 Q5 2018-2019 Q1 Q2 Q3 Q4 Q5 2017-2018 Q1 Q2 Q3 Q4 Q5 2016-2017 Q1 Q2 Q3 Q4 Q5 2015-2016 Q1 Q2 Q3 Q4 Q5
- [Familiarization program for Independent Directors](https://www.lincolnpharma.com/investor/disclosures-under-regulation-46-of-the-lodr/familiarization-program-for-independent-directors/) - 2022-2023 Q1 Q2 Q3 Q4 Q5 2021-2022 Q1 Q2 Q3 Q4 Q5 2020-2021 Q1 Q2 Q3 Q4 Q5 2019-2020 Q1 Q2 Q3 Q4 Q5 2018-2019 Q1 Q2 Q3 Q4 Q5 2017-2018 Q1 Q2 Q3 Q4 Q5 2016-2017 Q1 Q2 Q3 Q4 Q5 2015-2016 Q1 Q2 Q3 Q4 Q5
- [Detail of Business](https://www.lincolnpharma.com/investor/disclosures-under-regulation-46-of-the-lodr/detail-of-business/) - Detail of Business2022-2023 Q1 Q2 Q3 Q4 Q5 2021-2022 Q1 Q2 Q3 Q4 Q5 2020-2021 Q1 Q2 Q3 Q4 Q5 2019-2020 Q1 Q2 Q3 Q4 Q5 2018-2019 Q1 Q2 Q3 Q4 Q5 2017-2018 Q1 Q2 Q3 Q4 Q5 2016-2017 Q1 Q2 Q3 Q4 Q5 2015-2016 Q1 Q2 Q3 Q4 Q5
- [Policy on Related Party Transactions](https://www.lincolnpharma.com/investor/disclosures-under-regulation-46-of-the-lodr/policy-on-related-party-transactions/) - 2022-2023 Q1 Q2 Q3 Q4 Q5 2021-2022 Q1 Q2 Q3 Q4 Q5 2020-2021 Q1 Q2 Q3 Q4 Q5 2019-2020 Q1 Q2 Q3 Q4 Q5 2018-2019 Q1 Q2 Q3 Q4 Q5 2017-2018 Q1 Q2 Q3 Q4 Q5 2016-2017 Q1 Q2 Q3 Q4 Q5 2015-2016 Q1 Q2 Q3 Q4 Q5
- [Policy for determining ‘Material’ subsidiaries](https://www.lincolnpharma.com/investor/disclosures-under-regulation-46-of-the-lodr/policy-for-determining-material-subsidiaries/) - 2022-2023 Q1 Q2 Q3 Q4 Q5 2021-2022 Q1 Q2 Q3 Q4 Q5 2020-2021 Q1 Q2 Q3 Q4 Q5 2019-2020 Q1 Q2 Q3 Q4 Q5 2018-2019 Q1 Q2 Q3 Q4 Q5 2017-2018 Q1 Q2 Q3 Q4 Q5 2016-2017 Q1 Q2 Q3 Q4 Q5 2015-2016 Q1 Q2 Q3 Q4 Q5
- [Details of establishment of Whistle Blower Policy](https://www.lincolnpharma.com/investor/disclosures-under-regulation-46-of-the-lodr/details-of-establishment-of-whistle-blower-policy/) - 2022-2023 Q1 Q2 Q3 Q4 Q5 2021-2022 Q1 Q2 Q3 Q4 Q5 2020-2021 Q1 Q2 Q3 Q4 Q5 2019-2020 Q1 Q2 Q3 Q4 Q5 2018-2019 Q1 Q2 Q3 Q4 Q5 2017-2018 Q1 Q2 Q3 Q4 Q5 2016-2017 Q1 Q2 Q3 Q4 Q5 2015-2016 Q1 Q2 Q3 Q4 Q5
- [Code of conduct for Board of Directors & Senior Management Personnel](https://www.lincolnpharma.com/investor/disclosures-under-regulation-46-of-the-lodr/code-of-conduct-for-board-of-directors-senior-management-personnel/) - 2022-2023 Q1 Q2 Q3 Q4 Q5 2021-2022 Q1 Q2 Q3 Q4 Q5 2020-2021 Q1 Q2 Q3 Q4 Q5 2019-2020 Q1 Q2 Q3 Q4 Q5 2018-2019 Q1 Q2 Q3 Q4 Q5 2017-2018 Q1 Q2 Q3 Q4 Q5 2016-2017 Q1 Q2 Q3 Q4 Q5 2015-2016 Q1 Q2 Q3 Q4 Q5
- [Composition of various committees of Board of Directors](https://www.lincolnpharma.com/investor/disclosures-under-regulation-46-of-the-lodr/composition-of-various-committees-of-board-of-directors/) - Financial Results2022-2023 Q1 Q2 Q3 Q4 Q5 2021-2022 Q1 Q2 Q3 Q4 Q5 2020-2021 Q1 Q2 Q3 Q4 Q5 2019-2020 Q1 Q2 Q3 Q4 Q5 2018-2019 Q1 Q2 Q3 Q4 Q5 2017-2018 Q1 Q2 Q3 Q4 Q5 2016-2017 Q1 Q2 Q3 Q4 Q5 2015-2016 Q1 Q2 Q3 Q4 Q5
- [Terms and conditions of appointment of Independent Directors](https://www.lincolnpharma.com/investor/disclosures-under-regulation-46-of-the-lodr/terms-and-conditions-of-appointment-of-independent-directors/) - Financial Results2022-2023 Q1 Q2 Q3 Q4 Q5 2021-2022 Q1 Q2 Q3 Q4 Q5 2020-2021 Q1 Q2 Q3 Q4 Q5 2019-2020 Q1 Q2 Q3 Q4 Q5 2018-2019 Q1 Q2 Q3 Q4 Q5 2017-2018 Q1 Q2 Q3 Q4 Q5 2016-2017 Q1 Q2 Q3 Q4 Q5 2015-2016 Q1 Q2 Q3 Q4 Q5
- [India Operations](https://www.lincolnpharma.com/domestic/india-operations/) - India Operations Established in the year 1979, Lincoln Pharmaceuticals Limited is one of the leading healthcare companies in Gujarat, India. Company develops and manufactures affordable and innovative medicines for healthier lives. The company has developed 300 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynecology, cardio &
- [Innovation](https://www.lincolnpharma.com/r-d/innovation/) - Innovation @ Lincoln (Patents & First launches) Company’s innovation program is spearheaded by over 50 researchers working on differentiated medicines for the future. Company’s key strength is embedded in its cutting-edge research and development capabilities and It has successfully filled 25 plus patent applications and is awarded seven patents. Innovations at Lincoln have resulted in
- [Infrastructure](https://www.lincolnpharma.com/r-d/infrastructure/) - State-of-the-art R&D center The company has a state-of-the-art R&D center in Khatraj, Ahmedabad, which was setup in the year 2000 and approved by the Department of Scientific and Industrial Research, Govt. of India, Understanding highest moral responsibilities, Lincoln Pharmaceutical’s R&D center has pledged towards creating technology-based products at competitive prices for the patients. R&D center
- [Highlights](https://www.lincolnpharma.com/r-d/highlights/) - Passion for Research Passion for innovation and excellence drives the Research & Development activity at Lincoln Pharma. The company has a strong R&D team including 40 plus scientists. Company’s innovation program is spearheaded by over 20 researchers working on differentiated medicines for the future. Company’s key strength is embedded in its cutting-edge research and development
- [Sample Page](https://www.lincolnpharma.com/sample-page/) - Share Holding Pattern2011201220132011 Quarter ended Mar’11 Quarter ended Jun’11 Quarter ended Sep’11 Quarter ended Dec’11 2012 Quarter ended Mar’11 Quarter ended Jun’11 Quarter ended Sep’11 Quarter ended Dec’11 2013 Quarter ended Mar’11 Quarter ended Jun’11 Quarter ended Sep’11 Quarter ended Dec’11
- [At a Glance](https://www.lincolnpharma.com/manufacturing/at-a-glance/)
- [Quality Control & Assurance](https://www.lincolnpharma.com/manufacturing/quality-control-assurance/) - Lincoln’s Pledge We put required emphasis on quality control and carry appropriate safeguards to assure there aren’t any lapses on the production front. We, at Lincoln Pharmaceuticals, strongly emphasize on the ideology that level of quality is simply not spoken straight into a product, nevertheless must always exist naturally. The organization’s initiatives in direction of
- [Acts of Science](https://www.lincolnpharma.com/r-d/acts-of-science/) - Key Activities of the Formulation Scientist Development of parenteral formulations and analytical methods for in-process testing. Conduct and lead pre-formulation and formulation activities of in-house new developed products and line extensions. Perform method validation/qualification for in-process testing. Perform, track and monitor stability testing as required. Draft batch records, supervise the manufacture of Exhibit batches and
- [EHS Policy](https://www.lincolnpharma.com/manufacturing/ehs-policy/) - Environment Health and Safety Policy Lincoln Pharmaceuticals Ltd is fully committed to and continuously endeavors to achieve environment, health and safety excellence across its manufacturing and R&D facilities. The Company continues to invest required resources towards sustaining and continuously improving the standards of environment, occupational health and safety As a company we believes that its responsibility
- [International Business](https://www.lincolnpharma.com/international/international-business/) - OUR AGENCYGlobal ReachPresence in 60+ countries and counting… The company has a presence in more than 60 countries encompassing Africa, Central America and Southeast Asia and expanding its presence gradually in more countries. Company has also got many product registrations in countries like East and West Africa, South East Asia and Latin America. Exports have
- [Divisions](https://www.lincolnpharma.com/domestic/divisions/) - Pharma Holds this distinction of being the main division of Lincoln Pharmaceuticals Limited showcasing the flagship brand of Nam Cold along with leading focus in Anti Cold, Antibiotic, Otolaryngology and Pain Management with an incredibly diverse portfolio. Lords This division primarily serves Gastro, Pain Management &Anti-Malarial segment with leader brand ARH. Teresa This division is
- [Product Portfolio](https://www.lincolnpharma.com/portfolio/product-portfolio/)
- [Key Brands](https://www.lincolnpharma.com/portfolio/key-brands/) - Lincoln Pharmaceuticals Ltd presents an extensive range of branded and generic formulations, in compliance with international and national regulations, that cater to diverse therapeutic segments. The company has developed 300 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynecology, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others.
- [International Products](https://www.lincolnpharma.com/international/international-products/)
- [Therapeutic Coverage](https://www.lincolnpharma.com/domestic/therapeutic-coverage/) - Lincoln Pharmaceuticals Ltd presents an extensive range of branded and generic formulations, in compliance with international and national regulations, that cater to diverse therapeutic segments.
- [Portfolio](https://www.lincolnpharma.com/portfolio/)
- [International](https://www.lincolnpharma.com/international/)
- [Domestic](https://www.lincolnpharma.com/domestic/)
- [Therapy Wise details](https://www.lincolnpharma.com/therapy-wise-details/)
- [Manufacturing](https://www.lincolnpharma.com/manufacturing/)
- [Publications](https://www.lincolnpharma.com/publications/)
- [R & D](https://www.lincolnpharma.com/r-d/)

## Job Openings

- [Quality Control (HPLC)](https://www.lincolnpharma.com/jobs/quality-control-hplc/) - Quality Control (HPLC)
- [Production – Packing Officers (OSD)](https://www.lincolnpharma.com/jobs/production-packing-officers-osd/) - Production – Packing Officers (OSD)
- [Quality Control - Microbiologist](https://www.lincolnpharma.com/jobs/quality-control-microbiologist-2/) - Quality Control - Microbiologist
- [Quality Control - Sr. Microbiologist](https://www.lincolnpharma.com/jobs/quality-control-sr-microbiologist/) - Quality Control - Sr. Microbiologist
- [Production – Oral Liquid](https://www.lincolnpharma.com/jobs/production-packing-oral-liquid/) - Production – Oral Liquid
- [Quality Control - GLP](https://www.lincolnpharma.com/jobs/quality-control-glp/) - Quality Control GLP
- [Production - Officer to Sr. Executive](https://www.lincolnpharma.com/jobs/production-officer-to-sr-executive/) - Key Responsibilities: Responsible for tablets granulation, compression, coating and packing department. To execute production activities in a shift by managing available resources to achieve production target. To maintain standard process parameters as per BMR's and other supporting documents for achieving production target and maintaining quality. Prepare of Master Documents, BMR & BPR. To ensure and
- [Quality Assurance – (IPQA -Injectable)](https://www.lincolnpharma.com/jobs/quality-assurance-ipqa-injectable/) - Key Responsibilities : Handling cleaning validation/verification activity
- [ADL – Method Development](https://www.lincolnpharma.com/jobs/adl-method-development/) - Key Responsibilities: Use of HPLC/GC/UV/Dissolution apparatus. Dissolution development and impurity profiling. Force degradation study for FP and API. Pharmacopeia method interpretation, Literature/references search. Listing the requirements for method development. Review and interpretation of development trial data. Preparation and review of method development protocol and report. Descriptive method right up. Designation: Jr. Officer / Officer /
- [ADL – Stability Study](https://www.lincolnpharma.com/jobs/adl-stability-study/) - Key Responsibilities: Adequate knowledge of respective guidelines. i.e. ICH, USP,WHO, etc. Stability sample analysis by HPLC/GC/UV/Dissolution apparatus. Preparation of stability testing worksheets. Sample charge and withdrawal as per stability condition. Management of stability samples and stability chambers and maintain the schedule. Preparation of stability trend records and summarize the results Analysis planning, reporting and reviewing
- [ADL – Operation & Review](https://www.lincolnpharma.com/jobs/adl-operation-review/) - Key Responsibilities: Development and validation of GC Method Routine sample analysis Calibration, Maintenance, trouble shooting Follow Safety, data integrity and documentation practices Review raw data, integration and calculations Writing method and review. Prepare validation protocol, report and review Support regulatory submission with technical summaries and justifications. Designation: Officer / Sr.Officer / Executive / Sr. Executive
- [Quality Control – PM Sample Testing](https://www.lincolnpharma.com/jobs/quality-control-pm-sample-testing/) - Quality Control
- [ADL – Method Validation](https://www.lincolnpharma.com/jobs/adl-method-validation/) - Key Responsibilities: Use of HPLC/GC/UV/Dissolution apparatus. Adequate knowledge of respective guidelines. i.e. ICH, USP,WHO, etc. Integration for Assay and RS. Preparation of method validation protocol and report. Preparation and review of excel sheet for calculations. Review of method validation data. Designation: Jr. Officer / Officer / Sr.Officer / Executive Vacancy : 3 nos. Experience: 2
- [F&D – Documentation](https://www.lincolnpharma.com/jobs/fd-documentation/) - Key Responsibilities: Experience on Daily monitoring and control of environmental condition of F&D area Daily review and knowledge of verification and calibration of all equipment. Internal CCP, correspondence of all TTD related activity and compilation of all documents. Correspondence of IRA dossier related activity like review of PDR, MFR etc. IRA related EB batches BMR,
- [Production – Dry Powder Injection](https://www.lincolnpharma.com/jobs/production-dry-powder-injection/) - Production – Oral Liquid
- [Quality Assurance – IPQA (OSD)](https://www.lincolnpharma.com/jobs/quality-assurance-ipqa-osd/) - Handling of all IPQA activities during Manufacturing of Oral Solid dosage forms (Tablet and Capsule.) Line clearance during daily activities of production. Calculation of API and ingredients in dispensing activities. Logbook Review. Collection of samples in intermediate and finished stage in manufacturing of Tablets and Capsules. Perform Composite Sampling & Blend uniformity (BU). Record and
- [Quality Assurance – Walkin Drive](https://www.lincolnpharma.com/jobs/quality-assurance/)
- [Production OSD – Walkin Drive](https://www.lincolnpharma.com/jobs/production-osd/)
- [Production Inj. – Walkin Drive](https://www.lincolnpharma.com/jobs/production-inj/)
- [Warehouse RM – Walkin Drive](https://www.lincolnpharma.com/jobs/warehouse-rm/)
- [Quality Control Micro – Walkin Drive](https://www.lincolnpharma.com/jobs/quality-control-micro/)
- [Quality Control – Walkin Drive](https://www.lincolnpharma.com/jobs/quality-control/)
- [ADL – Walkin Drive](https://www.lincolnpharma.com/jobs/adl/)
- [F&D – Walkin Drive](https://www.lincolnpharma.com/jobs/fd/)
- [PPMC – Walkin Drive](https://www.lincolnpharma.com/jobs/ppmc/)
- [Engineering – Walkin Drive](https://www.lincolnpharma.com/jobs/engineering/)
- [Operator – Production – Walkin Drive](https://www.lincolnpharma.com/jobs/operator-production/)
- [Operator – Engineering – Walkin Drive](https://www.lincolnpharma.com/jobs/operator-engineering/)
- [Fresher’s Bcom – Walkin Drive](https://www.lincolnpharma.com/jobs/freshers-bcom/)
- [Fresher’s Science Graduate - Walkin Drive](https://www.lincolnpharma.com/jobs/freshers-science-graduate/)
- [Walk In Application](https://www.lincolnpharma.com/jobs/job-application/)

## Photo Albums

- [Green Day](https://www.lincolnpharma.com/dt_gallery/green-day/)

## 3D FlipBook

- [Lincoln Voice : Vol. 3](https://www.lincolnpharma.com/3d-flip-book/lincoln-voice-vol-3/)
- [Lincoln Voice : Vol. 2](https://www.lincolnpharma.com/3d-flip-book/lincoln-voice-vol-2/)
- [Lincoln Voice : Vol. 1](https://www.lincolnpharma.com/3d-flip-book/lincoln-voice-vol-1/)

## Categories

- [News](https://www.lincolnpharma.com/category/news/)
- [Innovation](https://www.lincolnpharma.com/category/innovation/)
- [Marketing](https://www.lincolnpharma.com/category/marketing/)

## Tags

- [article](https://www.lincolnpharma.com/tag/article/)
- [blog](https://www.lincolnpharma.com/tag/blog/)
- [life](https://www.lincolnpharma.com/tag/life/)
- [news](https://www.lincolnpharma.com/tag/news/)
- [world](https://www.lincolnpharma.com/tag/world/)
- [lincoln](https://www.lincolnpharma.com/tag/lincoln/)
- [pharma](https://www.lincolnpharma.com/tag/pharma/)
- [iifl](https://www.lincolnpharma.com/tag/iifl/)
- [international](https://www.lincolnpharma.com/tag/international/)
- [business](https://www.lincolnpharma.com/tag/business/)
- [halftime](https://www.lincolnpharma.com/tag/halftime/)
- [cnbc](https://www.lincolnpharma.com/tag/cnbc/)
- [tv18](https://www.lincolnpharma.com/tag/tv18/)
- [bse](https://www.lincolnpharma.com/tag/bse/)
- [ETnow](https://www.lincolnpharma.com/tag/etnow/)

## Album Categories

- [Navratri](https://www.lincolnpharma.com/dt_gallery_category/navratri/)

## Qualification

- [B.Pharm](https://www.lincolnpharma.com/qualification/b-pharm/)
- [M.Pharm](https://www.lincolnpharma.com/qualification/m-pharm/)
- [MSc](https://www.lincolnpharma.com/qualification/msc/)
- [BSc](https://www.lincolnpharma.com/qualification/bsc/)
- [D.Pharm](https://www.lincolnpharma.com/qualification/d-pharm/)
- [Any Graduate](https://www.lincolnpharma.com/qualification/any-graduate/)
- [B.A](https://www.lincolnpharma.com/qualification/b-a/)
- [Bcom](https://www.lincolnpharma.com/qualification/bcom/)

## Job Category

- [Quality Assurance](https://www.lincolnpharma.com/job-category/quality-assurance/)
- [Production](https://www.lincolnpharma.com/job-category/production/)
- [Quality Control](https://www.lincolnpharma.com/job-category/quality-control/)
- [Manufacturing](https://www.lincolnpharma.com/job-category/manufacturing/)
- [Analytical Development](https://www.lincolnpharma.com/job-category/analytical-development/)

## Job Type

- [Full Time](https://www.lincolnpharma.com/job-type/full-time/)

## Job Location

- [Khatraj](https://www.lincolnpharma.com/job-location/khatraj/)

## Department

- [Production OSD](https://www.lincolnpharma.com/department/production-osd/)
- [Production Inj.](https://www.lincolnpharma.com/department/production-inj/)
- [Warehouse RM](https://www.lincolnpharma.com/department/warehouse-rm/)
- [Quality Control Micro](https://www.lincolnpharma.com/department/quality-control-micro/)
- [Quality Control](https://www.lincolnpharma.com/department/quality-control/)
- [Quality Assurance](https://www.lincolnpharma.com/department/quality-assurance/)
- [ADL](https://www.lincolnpharma.com/department/adl/)
- [F&D](https://www.lincolnpharma.com/department/fd/)
- [PPMC](https://www.lincolnpharma.com/department/ppmc/)
- [Engineering](https://www.lincolnpharma.com/department/engineering/)
- [Operator – Production](https://www.lincolnpharma.com/department/operator-production/)
- [Operator – Engineering](https://www.lincolnpharma.com/department/operator-engineering/)
- [Fresher’s Bcom](https://www.lincolnpharma.com/department/freshers-bcom/)
- [Fresher’s Science Graduate](https://www.lincolnpharma.com/department/freshers-science-graduate/)
- [Production](https://www.lincolnpharma.com/department/production/)
- [R&D](https://www.lincolnpharma.com/department/rd/)